Advertisement
CRON vs YCBD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a Buy and YCBD is a Buy.
CRON in upward trend: price rose above 50-day moving average on October 20, 2026
CRON moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 61 of 71 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CRON as a result. In 89 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on October 21, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in 49 of 59 cases over the following month. The odds of a continued upward trend are 83%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 168 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRON moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 55 cases where CRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The 10-day moving average for CRON crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
CRON broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.141) is normal, around the industry mean (8.413). P/E Ratio (17.421) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
YCBD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for YCBD turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 37 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Oscillator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 69 of 79 cases where YCBD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 85 of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
YCBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.498) is normal, around the industry mean (8.413). P/E Ratio (1.586) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
CRON | YCBD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 98 | |
PRICE GROWTH RATING 1..100 | 41 | 88 | |
P/E GROWTH RATING 1..100 | 94 | 69 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
YCBD's Valuation (41) in the Other Consumer Services industry is in the same range as CRON (52) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CRON’s over the last 12 months.
YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CRON’s over the last 12 months.
CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as YCBD (98) in the Other Consumer Services industry. This means that CRON’s stock grew similarly to YCBD’s over the last 12 months.
CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for YCBD (88) in the Other Consumer Services industry. This means that CRON’s stock grew somewhat faster than YCBD’s over the last 12 months.
YCBD's P/E Growth Rating (69) in the Other Consumer Services industry is in the same range as CRON (94) in the Pharmaceuticals Other industry. This means that YCBD’s stock grew similarly to CRON’s over the last 12 months.
| CRON | YCBD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Advances ODDS (%) | 5 days ago 73% | N/A |
| Declines ODDS (%) | 1 day ago 76% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| Aroon ODDS (%) | N/A | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRON’s FA Score shows that 0 FA rating(s) are green while YCBD’s FA Score has 0 green FA rating(s).
- CRON’s FA Score: 0 green, 5 red.
- YCBD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRON’s TA Score shows that 4 TA indicator(s) are bullish while YCBD’s TA Score has 5 bullish TA indicator(s).
- CRON’s TA Score: 4 bullish, 5 bearish.
- YCBD’s TA Score: 5 bullish, 2 bearish.
Price Growth
CRON (@Pharmaceuticals: Generic) experienced а +1.85% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was +4.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.57%. For the same industry, the average monthly price growth was -11.91%, and the average quarterly price growth was +7.55%.
Reported Earning Dates
CRON is expected to report earnings on Nov 05, 2026.
YCBD is expected to report earnings on Dec 18, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.57% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CRON and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | -1.19% | ||
| SNDL - CRON | 73% Closely correlated | -1.55% | ||
| ACB - CRON | 59% Loosely correlated | +0.52% | ||
| TLRY - CRON | 58% Loosely correlated | -3.20% | ||
| CGC - CRON | 58% Loosely correlated | -1.14% | ||
| TRLV - CRON | 55% Loosely correlated | +3.84% | ||
More | ||||
YCBD and
Correlation & Price change
A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TLRY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TLRY could also see price increases.
| Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
|---|---|---|---|---|
| YCBD | 100% | +0.61% | ||
| TLRY - YCBD | 58% Loosely correlated | -3.20% | ||
| TRLV - YCBD | 48% Loosely correlated | +3.84% | ||
| GLAS - YCBD | 43% Loosely correlated | N/A | ||
| CRON - YCBD | 40% Loosely correlated | -1.19% | ||
| DERM - YCBD | 24% Poorly correlated | -1.00% | ||
More | ||||